A new clinical trial is evaluating whether the combination of evofosfamide, a hypoxia-activated drug, with checkpoint inhibitors zalifrelimab and balstilimab can improve outcomes in advanced cancers.
Evofosfamide targets oxygen-deprived areas in tumors, helping the immune system reach cancer cells previously shielded by hypoxia.
Researchers hope that disrupting the tumor’s protective environment will enhance the effectiveness of immune checkpoint inhibitors. If successful, this combination could offer new treatment options for patients whose cancers have resisted other therapies.
So I would say: we are actually testing evofosfamide, if it works, then we will attach everything we can to it and carpet bomb the tumor micro environment!
SGLT-2 Inhibitors to (partially) “Starve” Glucose Dependent Cancers
OVM-200 Phase 1 clinical trial ( vaccine)